58 results
8-K
EGRX
Eagle Pharmaceuticals Inc
29 Feb 24
Cost Associated with Exit or Disposal Activities
8:09am
expects that the majority of the above estimated charges related to the Realignment Plan will be recorded in the first quarter of 2024
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals Inc
24 Jul 23
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century1
7:00am
specifically caused the infection. Because CAL02 relies on mechanics common across a vast majority of virulence factors produced by the most common pathogens
8-K
EX-99.1
EGRX
Eagle Pharmaceuticals Inc
6 Dec 22
Regulation FD Disclosure
7:31am
physician partners majority owners of the practice–800 employed physicians–2,600 CRNAs and AAs700 facilities served:–200 hospitals–250 ASCs25 healthcare
8-K
vggra
2 Nov 22
Entry into a Material Definitive Agreement
5:49pm
8-K
EX-10.1
tdiq6hxd5 j18r
2 Nov 22
Entry into a Material Definitive Agreement
5:49pm
8-K/A
EX-99.1
pd4 0slt5k
25 Aug 22
Report of Independent Auditors
5:01pm
8-K
EX-10.2
qmu0858nebrqmmwswvkf
9 Aug 22
Eagle Pharmaceuticals Reports Second Quarter 2022 Results
8:26am
8-K
EX-10.1
069qz
9 Aug 22
Eagle Pharmaceuticals Reports Second Quarter 2022 Results
8:26am
8-K
ddtcyq mkdcbs4hi07x
9 Aug 22
Eagle Pharmaceuticals Reports Second Quarter 2022 Results
8:26am
8-K/A
t6db13jni
4 Aug 22
Submission of Matters to a Vote of Security Holders
8:11am
8-K
pkd9f
9 Jun 22
Entry into a Material Definitive Agreement
8:33am
8-K
EX-99.1
epyb5kg2nnp qi1sqj
27 Apr 22
Regulation FD Disclosure
6:01am